<DOC>
	<DOCNO>NCT02582879</DOCNO>
	<brief_summary>The purpose InformCLL Registry characterize describe treatment pattern initiate treatment approve oral kinase inhibitor , BCL-2 inhibitor approve anti-CLL /SLL therapies/regimens . This study also evaluate association treatment pattern patient characteristic , healthcare resource utilization patient report Health related Quality Life ( HRQoL ) .</brief_summary>
	<brief_title>informCLL™ : A Disease Registry Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>InformCLL multicenter , prospective , observational registry CLL patient design characterize describe treatment pattern initiate treatment approve oral kinase inhibitor , BCL-2 inhibitor approve anti-CLL therapies/regimens . The registry provide information regimen use treat first-line later line CLL/SLL well sequence treatment regimen . The registry also evaluate association treatment pattern patient characteristic , healthcare resource utilization , functional outcome include patient-reported HRQoL . These data provide information physician may help guide clinical practice appropriate use therapy , also provide information HRQoL healthcare resource utilization interest healthcare decision maker .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Age least 18 year Clinical diagnosis CLL/SLL meet publish diagnostic criterion ( Hallek 2008 ) Initiating treatment within ±30 day enrollment novel therapy include oral kinase inhibitor ( e.g. , inhibitor BTK [ e.g. , ibrutinib ] , inhibitor BCL2 pathway [ e.g venetoclax ] PI3K [ e.g. , idelalisib ] ) , antiCLL therapies/regimens approve time patient enrollment Availability documentation previous CLL/SLL treatment duration response patient 's medical record Willing able provide inform consent Willing able complete PRO instrument Willing able provide information patient survey questionnaire Willing able provide blood sample time enrollment Diagnosis Bcell malignancy CLL/SLL Estimated life expectancy &lt; 6 month Currently receive treatment interventional clinical trial nonapproved , investigational agent CLL/SLL study entry ( note : patient enroll interventional clinical trial enrollment may remain registry )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>Small Lymphocytic Leukemia</keyword>
	<keyword>SLL</keyword>
</DOC>